Renren Bai

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 18

Top Venues

Journal of medicinal chemistry

Medicinal research reviews

Drug development research

Molecules (Basel, Switzerland)

Emory University

China Pharmaceutical University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Emory University Aug 11 2014

United States

Post-doc :: Department of Radiology

Education History

China Pharmaceutical University Sep 10 2008 - Jun 30 2013

China

PHD :: Department of Medicinal Chemistry

Publications

Xiaoying Jiang, Liuxin Lu, Junjie Li, Jing Jiang, Jiapeng Zhang, Shengbin Zhou, Hao Wen, Hong Cai, Xinyu Luo, Zhen Li, Jiahui Wang, Bin Ju, Renren Bai
Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4. Journal of medicinal chemistry 67 (12) (2024)
Liuxin Lu, Junjie Li, Xiaoying Jiang, Renren Bai
CXCR4/CXCL12 axis: "old" pathway as "novel" target for anti-inflammatory drug discovery. Medicinal research reviews 44 (3) (2024)
Liuxin Lu, Junjie Li, Xiaoying Jiang, Renren Bai
CXCR4/CXCL12 axis: "old" pathway as "novel" target for anti-inflammatory drug discovery. Medicinal research reviews (2024)
Xiaoying Jiang, Liuxin Lu, Junjie Li, Jing Jiang, Jiapeng Zhang, Shengbin Zhou, Hao Wen, Hong Cai, Xinyu Luo, Zhen Li, Jiahui Wang, Bin Ju, Renren Bai
Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4. Journal of medicinal chemistry 67 (12) (2024)
Liuxin Lu, Junjie Li, Xiaoying Jiang, Renren Bai
CXCR4/CXCL12 axis: "old" pathway as "novel" target for anti-inflammatory drug discovery. Medicinal research reviews 44 (3) (2024)
Liuxin Lu, Junjie Li, Xiaoying Jiang, Renren Bai
CXCR4/CXCL12 axis: "old" pathway as "novel" target for anti-inflammatory drug discovery. Medicinal research reviews 44 (3) (2024)
Xiaoying Jiang, Liuxin Lu, Junjie Li, Jing Jiang, Jiapeng Zhang, Shengbin Zhou, Hao Wen, Hong Cai, Xinyu Luo, Zhen Li, Jiahui Wang, Bin Ju, Renren Bai
Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4. Journal of medicinal chemistry (2024)
Hong Cai, Wenchao Chen, Jing Jiang, Hao Wen, Xinyu Luo, Junjie Li, Liuxin Lu, Rui Zhao, Xinhua Ni, Yinyan Sun, Jiahui Wang, Zhen Li, Bin Ju, Xiaoying Jiang, Renren Bai
Artificial Intelligence-Assisted Optimization of Antipigmentation Tyrosinase Inhibitors: De Novo Molecular Generation Based on a Low Activity Lead Compound. Journal of medicinal chemistry (2024)
Hong Cai, Wenchao Chen, Jing Jiang, Hao Wen, Xinyu Luo, Junjie Li, Liuxin Lu, Rui Zhao, Xinhua Ni, Yinyan Sun, Jiahui Wang, Zhen Li, Bin Ju, Xiaoying Jiang, Renren Bai
Artificial Intelligence-Assisted Optimization of Antipigmentation Tyrosinase Inhibitors: De Novo Molecular Generation Based on a Low Activity Lead Compound. Journal of medicinal chemistry 67 (9) (2024)
Junlong Zhu, Xiaoying Jiang, Xinyu Luo, Rui Zhao, Junjie Li, Hong Cai, Xiang-Yang Ye, Renren Bai, Tian Xie
Combination of chemotherapy and gaseous signaling molecular therapy: Novel β-elemene nitric oxide donor derivatives against leukemia. Drug development research (2023)
Xiaoying Jiang, Kaiyu Wu, Xiang-Yang Ye, Tian Xie, Pengfei Zhang, Benjamin E Blass, Renren Bai
Novel druggable mechanism of Parkinson's disease: Potential therapeutics and underlying pathogenesis based on ferroptosis. Medicinal research reviews (2023)
Li-Wei Wang, Songwei Jiang, Ying-Hui Yuan, Jilong Duan, Nian-Dong Mao, Zi Hui, Renren Bai, Tian Xie, Xiang-Yang Ye
Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR). Molecules (Basel, Switzerland) 27 (8) (2022)
Hong Yao, Giuseppe Uras, Pengfei Zhang, Shengtao Xu, Ying Yin, Jie Liu, Shuai Qin, Xinuo Li, Stephanie Allen, Renren Bai, Qi Gong, Hai Yan Zhang, Zheying Zhu, Jinyi Xu
Discovery of Novel Tacrine-Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer's Disease. Journal of medicinal chemistry 64 (11) (2021)
Suwen Hu, Songwei Jiang, Xiang Qi, Renren Bai, Xiang-Yang Ye, Tian Xie
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review. Drug development research (2021)
Xiaoying Jiang, Robert C Hider, Renren Bai, Yuan-Yuan Xie
Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities. Journal of medicinal chemistry 63 (23) (2020)
Renren Bai, Chengyun Zhang, Ling Wang, Chuansheng Yao, Jiamin Ge, Hongliang Duan
Transfer Learning: Making Retrosynthetic Predictions Based on a Small Chemical Reaction Dataset Scale to a New Level. Molecules (Basel, Switzerland) 25 (10) (2020)
Xingrui He, Xiao-Tao Zhuo, Yuan Gao, Renren Bai, Xiang-Yang Ye, Tian Xie
β-Elemene derivatives produced from SeO2-mediated oxidation reaction. Royal Society open science 7 (5) (2020)
Zili Guo, Xiaokang Jie, Peixi Zhu, Jian Sun, Jinping Gu, Feng Su, Renren Bai, Yuanyuan Xie
Fragmentation pathways of deprotonated amide-sulfonamide CXCR4 inhibitors investigated by ESI-IT-MSn , ESI-Q-TOF-MS/MS and DFT calculations. Journal of mass spectrometry : JMS 54 (11) (2019)

Renren Bai.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Renren Bai